Identification

Name
Doxylamine
Accession Number
DB00366  (APRD00937)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. [PubChem]

Structure
Thumb
Synonyms
  • 2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine
  • 2-Dimethylaminoethoxyphenylmethyl-2-picoline
  • Dossilamina
  • Doxilamina
  • Doxilminio
  • Doxylaminum
  • N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine
  • Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether
Product Ingredients
IngredientUNIICASInChI Key
Doxylamine succinateV9BI9B5YI2562-10-7KBAUFVUYFNWQFM-UHFFFAOYSA-N
Product Images
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
7 Select Sleep AidTablet25 mg/1Oral7 Eleven2014-08-05Not applicableUs
Care One Sleep AidTablet25 mg/1OralAmerican Sales Company2004-06-29Not applicableUs
CareOne Nighttime Sleep AidTablet25 mg/1OralAmerican Sales Company2016-05-06Not applicableUs
Equaline Sleep AidTablet25 mg/1OralSupervalu2004-08-10Not applicableUs
Good Neighbor Pharmacy Sleep AidTablet25 mg/1OralAmerisource Bergen1997-06-26Not applicableUs
Good sense sleep aidTablet25 mg/1OralL. Perrigo Company1997-04-14Not applicableUs
Harris Teeter Sleep AidTablet25 mg/1OralHarris Teeter2015-11-21Not applicableUs
Health Mart Sleep AidTablet25 mg/1OralMc Kesson2011-11-21Not applicableUs
Healthy Accents Sleep AidTablet25 mg/1OralDza Brands,2011-06-06Not applicableUs
Kirkland Signature Sleep AidTablet25 mg/1OralCostco Wholesale2003-06-272017-11-09Us
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
7 Select Night Time ReliefDoxylamine succinate (12.5 mg/30mL) + Acetaminophen (650 mg/30mL) + Dextromethorphan hydrobromide (30 mg/30mL)SolutionOral7 Eleven2014-08-05Not applicableUs
7 Select Night Time ReliefDoxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (15 mg/1)Capsule, gelatin coatedOral7 Eleven2014-04-17Not applicableUs
Acetaminophen Dextromethorphan HBr Doxylamine succinate Phenylephrine HClDoxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)Capsule, liquid filledOralCVS Health2017-11-30Not applicableUs
Acetaminophen Dextromethorphan HBr Doxylamine succinate Phenylephrine HClDoxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)Capsule, liquid filledOralCvs Pharmacy,inc2017-07-07Not applicableUs
ACETAMINOPHEN DEXTROMETHORPHAN HYDROBROMIDE and DOXYLAMINE SUCCINATEDoxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (15 mg/1)Capsule, liquid filledOralJ.P. BUSINESS ENTERPRISE2014-12-01Not applicableUs
Acetaminophen Dextromethorphan Hydrobromide Doxylamine Succinate Phenylephrine HydrochlorideDoxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)Capsule, liquid filledOralGranules India Limited2017-07-07Not applicableUs
ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, and DOXYLAMINE SUCCINATEDoxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (15 mg/1)Capsule, liquid filledOralSpirit Pharmaceuticals, Llc2009-10-15Not applicableUs
Acetaminophen,Dextromethorphan,DoxylamineDoxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1)Capsule, liquid filledOralAgile Pharmachem2014-05-01Not applicableUs
Acetaminophen/pseudoephedrine/dextromethorphan/doxylamineDoxylamine succinate (6.25 mg) + Acetaminophen (325 mg) + Dextromethorphan hydrobromide (15 mg) + Pseudoephedrine hydrochloride (30 mg)CapsuleOralApotex CorporationNot applicableNot applicableCanada
Alka-Seltzer Plus Day and Night Cold and Flu FormulaDoxylamine succinate + Acetaminophen + Dextromethorphan hydrobromide + Phenylephrine hydrochlorideKitBayer Health Care Llc.2013-10-302018-08-31Us
Categories
UNII
95QB77JKPL
CAS number
469-21-6
Weight
Average: 270.3694
Monoisotopic: 270.173213336
Chemical Formula
C17H22N2O
InChI Key
HCFDWZZGGLSKEP-UHFFFAOYSA-N
InChI
InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3
IUPAC Name
dimethyl({2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethyl})amine
SMILES
CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1

Pharmacology

Indication

Used alone as a short-term sleep aid, in combination with other drugs as a night-time cold and allergy relief drug. Also used in combination with Vitamin B6 (pyridoxine) to prevent morning sickness in pregnant women.

Structured Indications
Pharmacodynamics

Doxylamine is an antihistamine commonly used as a sleep aid. This drug is also used to relieve symptoms of hay fever (allergic rhinitis), hives (rash or itching), and other allergic reactions. Doxylamine is a member of the ethanolamine class of antihistamines and has anti-allergy power far superior to virtually every other antihistamine on the market, with the exception of diphenhydramine (Benadryl). It is also the most powerful over-the-counter sedative available in the United States, and more sedating than many prescription hypnotics. In a study, it was found to be superior to even the barbiturate, phenobarbital for use as a sedative. Doxylamine is also a potent anticholinergic.

Mechanism of action

Like other antihistamines, doxylamine acts by competitively inhibiting histamine at H1 receptors. It also has substantial sedative and anticholinergic effects.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
UMuscarinic acetylcholine receptor M1
antagonist
Human
UNuclear receptor subfamily 1 group I member 3Not AvailableHuman
Absorption

Readily absorbed via the gastrointestinal tract.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination
Not Available
Half life

10 hours

Clearance
Not Available
Toxicity

Signs of overdose include wheezing, tightness in the chest, fever, itching, bad cough, blue skin color, fits, swelling of face, lips, tongue, or throat.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Doxylamine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Doxylamine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Doxylamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Doxylamine.Experimental, Illicit
7-NitroindazoleDoxylamine may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the anticholinergic activities of Doxylamine.Experimental
AcepromazineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved, Vet Approved
AceprometazineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
AdipiplonDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Adipiplon.Investigational
AgomelatineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Doxylamine is combined with Alaproclate.Experimental
AlfaxaloneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Vet Approved
AlfentanilDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.Approved, Illicit
AllopregnanoloneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Allopregnanolone.Investigational
AlphacetylmethadolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Alphaprodine.Illicit
AlprazolamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Illicit, Investigational
AmisulprideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Investigational
AmitriptylineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
AmobarbitalDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved, Illicit
AmoxapineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
AmperozideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Experimental
AmphetamineAmphetamine may increase the anticholinergic activities of Doxylamine.Approved, Illicit
AripiprazoleDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Investigational
ArticaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved
AsenapineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved
AzaperoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Investigational, Vet Approved
AzelastineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Baclofen.Approved
BarbitalDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Barbital.Illicit
BenmoxinBenmoxin may increase the anticholinergic activities of Doxylamine.Withdrawn
BenperidolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Benperidol.Investigational
BenzocaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Doxylamine.Approved, Illicit
Benzyl alcoholDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineDoxylamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Doxylamine.Approved
BrexpiprazoleDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved
BrimonidineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved
BrofaromineBrofaromine may increase the anticholinergic activities of Doxylamine.Experimental
BromazepamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Illicit
BromisovalDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Bromisoval.Experimental
BromperidolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Bromperidol.Investigational
BrompheniramineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved
BrotizolamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Brotizolam.Approved, Investigational, Withdrawn
BupivacaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved, Investigational
BuprenorphineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Investigational
ButabarbitalDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved, Illicit
ButacaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Butacaine.Vet Approved
ButalbitalDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved, Illicit
ButambenDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved
ButethalDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Butethal.Approved, Illicit
ButorphanolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved, Illicit, Vet Approved
CanertinibDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Canertinib.Investigational
CarbamazepineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Investigational
CarbinoxamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved
CarfentanilDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
CaroxazoneCaroxazone may increase the anticholinergic activities of Doxylamine.Withdrawn
CetirizineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved
Chloral hydrateDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.Approved, Illicit
ChlormezanoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved
ChlorphenamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Doxylamine.Illicit, Withdrawn
ChlorpromazineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved
CinchocaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Doxylamine is combined with Citalopram.Approved
ClemastineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clemastine.Approved
ClidiniumDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved
ClobazamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clobazam.Approved, Illicit
clomethiazoleDoxylamine may increase the central nervous system depressant (CNS depressant) activities of clomethiazole.Investigational
ClomipramineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved, Vet Approved
ClonazepamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved, Illicit
ClonidineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved
ClopenthixolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clopenthixol.Experimental
ClorazepateDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Illicit
ClothiapineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clothiapine.Experimental
ClozapineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved
CocaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.Approved, Illicit
CodeineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Illicit
CyclizineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.Approved
CyclobenzaprineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
CyproheptadineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved
DantroleneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
DapiprazoleDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Dapoxetine.Investigational
DeramciclaneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Deramciclane.Investigational
DesfluraneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved
DesipramineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved
DesloratadineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Desvenlafaxine.Approved
DetomidineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Detomidine.Vet Approved
DexbrompheniramineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
DexmedetomidineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Doxylamine.Approved, Illicit
DextromoramideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dezocine.Approved, Investigational
DiazepamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Diazepam.Approved, Illicit, Vet Approved
Diethyl etherDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Diethyl ether.Experimental
DiethylpropionDiethylpropion may decrease the sedative activities of Doxylamine.Approved, Illicit
DifenoxinDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Difenoxin.Approved, Illicit
DihydrocodeineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Experimental, Illicit
DimenhydrinateDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
DiphenhydramineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved
DiphenoxylateDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved, Illicit
DixyrazineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dixyrazine.Experimental
DoramectinDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Doramectin.Vet Approved
DoxepinDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved
DPDPEDoxylamine may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved, Vet Approved
DrotebanolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Duloxetine.Approved
DyclonineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
EcgonineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ecgonine.Experimental, Illicit
EcopipamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Investigational
EfavirenzDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Investigational
EltanoloneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Eltanolone.Investigational
EnfluraneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Enflurane.Approved, Investigational, Vet Approved
EntacaponeDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Doxylamine is combined with Escitalopram.Approved, Investigational
EstazolamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Estazolam.Approved, Illicit
EszopicloneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved
EthchlorvynolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
EthotoinDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
Ethyl carbamateDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Withdrawn
Ethyl chlorideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethyl chloride.Experimental, Investigational
Ethyl loflazepateDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved, Illicit
EthylmorphineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved, Illicit
EtidocaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Etidocaine.Approved
EtifoxineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Etifoxine.Investigational, Withdrawn
EtizolamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Etizolam.Approved
EtomidateDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Doxylamine is combined with Etoperidone.Withdrawn
EtorphineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Etorphine.Illicit, Vet Approved
EzogabineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.Approved
FelbamateDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved
FencamfamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved, Illicit, Withdrawn
FentanylDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved
FlibanserinDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
FluanisoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluanisone.Experimental
FludiazepamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Illicit
FlunarizineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved
FlunitrazepamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Withdrawn
FluphenazineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
FlurazepamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved, Illicit
FluspirileneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved, Investigational
Fluticasone propionateDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.Approved
FluvoxamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved, Investigational
FosphenytoinDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.Approved
FospropofolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.Approved, Illicit, Investigational
FurazolidoneFurazolidone may increase the anticholinergic activities of Doxylamine.Approved, Investigational, Vet Approved
GabapentinDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
Gabapentin EnacarbilDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GepefrineGepefrine may decrease the sedative activities of Doxylamine.Experimental
GepironeDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Gepirone.Investigational
GlutethimideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Glutethimide.Approved, Illicit
GuanfacineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Investigational
HalazepamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Halazepam.Approved, Illicit, Withdrawn
HaloperidolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
HalothaneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved, Vet Approved
HarmalineHarmaline may increase the anticholinergic activities of Doxylamine.Experimental
HeroinDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Heroin.Approved, Illicit, Investigational
HexobarbitalDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Doxylamine.Approved, Investigational
HydracarbazineHydracarbazine may increase the anticholinergic activities of Doxylamine.Experimental
HydrocodoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Doxylamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved
IloperidoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
ImipramineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Indalpine.Investigational, Withdrawn
IndiplonDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Doxylamine.Approved
IproclozideIproclozide may increase the anticholinergic activities of Doxylamine.Withdrawn
IproniazidIproniazid may increase the anticholinergic activities of Doxylamine.Withdrawn
IsocarboxazidIsocarboxazid may increase the anticholinergic activities of Doxylamine.Approved
IsofluraneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.Approved, Vet Approved
KetamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Vet Approved
KetazolamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved
KetobemidoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved, Investigational
LamotrigineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Investigational
LevetiracetamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Investigational
LevobupivacaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Levobupivacaine.Approved, Investigational
LevocabastineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.Approved
LevocetirizineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved
LevodopaDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved
Levomethadyl AcetateDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Doxylamine is combined with Levomilnacipran.Approved
LevorphanolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved
LidocaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Doxylamine.Approved, Investigational
LithiumDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
LofentanilDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Lofentanil.Illicit
LoprazolamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Loprazolam.Experimental
LoratadineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved
LorazepamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved
LormetazepamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.Approved
LoxapineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved
LurasidoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved, Vet Approved
MaprotilineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
MebanazineMebanazine may increase the anticholinergic activities of Doxylamine.Withdrawn
MebicarDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Mebicar.Experimental
MeclizineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved
MedazepamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Medazepam.Experimental
MedetomidineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Medetomidine.Vet Approved
MelatoninDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Melperone.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Doxylamine.Investigational
MephentermineMephentermine may decrease the sedative activities of Doxylamine.Approved
MepivacaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Vet Approved
MeprobamateDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Illicit
MeptazinolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Meptazinol.Experimental
MesoridazineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved, Investigational
MetaxaloneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
MethadoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Doxylamine.Approved, Illicit
MethapyrileneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Withdrawn
MethaqualoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.Illicit, Withdrawn
MethocarbamolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
MethohexitalDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved
MethotrimeprazineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Doxylamine.Experimental
MethsuximideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
MethylecgonineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.Experimental
Methylene blueMethylene blue may increase the anticholinergic activities of Doxylamine.Approved, Investigational
MethylphenobarbitalDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved
MetyrosineDoxylamine may increase the sedative activities of Metyrosine.Approved
MidazolamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative activities of Doxylamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Doxylamine is combined with Milnacipran.Approved
MinaprineMinaprine may increase the anticholinergic activities of Doxylamine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved, Investigational
MirtazapineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may decrease the sedative activities of Doxylamine.Experimental, Illicit
MoclobemideMoclobemide may increase the anticholinergic activities of Doxylamine.Approved
MolindoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved
MorphineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved, Investigational
NalbuphineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Doxylamine is combined with Nefazodone.Approved, Withdrawn
NialamideNialamide may increase the anticholinergic activities of Doxylamine.Withdrawn
NitrazepamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved
Nitrous oxideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.Approved, Vet Approved
NorfluraneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Norflurane.Investigational
NormethadoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Normethadone.Approved, Illicit
NortriptylineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved
OctamoxinOctamoxin may increase the anticholinergic activities of Doxylamine.Withdrawn
OlanzapineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Investigational
OlopatadineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
OndansetronDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved
OpiumDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Opium.Approved, Illicit
OrphenadrineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Investigational
OxazepamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved
OxethazaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxethazaine.Approved, Investigational
OxprenololDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved
OxybuprocaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.Approved
OxycodoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Illicit, Investigational
OxymorphoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved, Investigational, Vet Approved
PaliperidoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
ParaldehydeDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylinePargyline may increase the anticholinergic activities of Doxylamine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Paroxetine.Approved, Investigational
PenfluridolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Penfluridol.Experimental
PentazocineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Vet Approved
PentobarbitalDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved
PerazineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Perazine.Investigational
PerospironeDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved
PerphenazineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved
PethidineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenazocineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenazocine.Experimental
PhenelzinePhenelzine may increase the anticholinergic activities of Doxylamine.Approved
PhenibutDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenibut.Experimental
PheniprazinePheniprazine may increase the anticholinergic activities of Doxylamine.Withdrawn
PhenobarbitalDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved
PhenoperidineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenoperidine.Experimental
PhenoxyethanolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenoxyethanol.Approved
PhenoxypropazinePhenoxypropazine may increase the anticholinergic activities of Doxylamine.Withdrawn
PhenterminePhentermine may decrease the sedative activities of Doxylamine.Approved, Illicit
PhenytoinDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.Approved, Vet Approved
PimozideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved
PipamperoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved, Investigational
PipotiazineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved, Investigational
PiritramideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Piritramide.Investigational
PirlindolePirlindole may increase the anticholinergic activities of Doxylamine.Approved
PivhydrazinePivhydrazine may increase the anticholinergic activities of Doxylamine.Withdrawn
PizotifenDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.Approved
PomalidomideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
PramipexoleDoxylamine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved
PrazepamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved, Illicit
PregabalinDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved, Illicit, Investigational
PrilocaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Prilocaine.Approved
PrimidoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Primidone.Approved, Vet Approved
ProcaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the anticholinergic activities of Doxylamine.Approved
ProchlorperazineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Vet Approved
PromazineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Vet Approved
PromethazineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved
PropanididDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Propanidid.Experimental
ProparacaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved, Vet Approved
PropofolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Investigational, Vet Approved
PropoxycaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Propoxycaine.Approved
ProtriptylineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
ProxibarbalDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Proxibarbal.Experimental
PSD502Doxylamine may increase the central nervous system depressant (CNS depressant) activities of PSD502.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Doxylamine.Approved
QuazepamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved, Illicit
QuetiapineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
QuinisocaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Quinisocaine.Experimental
RacloprideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Raclopride.Investigational
RamelteonDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved, Investigational
RasagilineRasagiline may increase the anticholinergic activities of Doxylamine.Approved
RemifentanilDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
RemoxiprideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Withdrawn
ReserpineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved, Investigational
RisperidoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Investigational
RitanserinDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ritanserin.Investigational
RitobegronRitobegron may decrease the sedative activities of Doxylamine.Investigational
RomifidineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Romifidine.Vet Approved
RopiniroleDoxylamine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved
RotigotineDoxylamine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Doxylamine.Approved
SafrazineSafrazine may increase the anticholinergic activities of Doxylamine.Withdrawn
ScopolamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
SecobarbitalDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the anticholinergic activities of Doxylamine.Approved, Investigational, Vet Approved
SepranoloneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Sepranolone.Investigational
SertindoleDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Sertraline.Approved
SevofluraneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved
StiripentolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.Approved
SufentanilDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Investigational
SulpirideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Investigational
SultoprideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Sultopride.Experimental
SuvorexantDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved
TasimelteonDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.Approved
TemazepamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved
TetrabenazineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved
TetracaineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved, Vet Approved
TetrahydropalmatineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Investigational
TetrodotoxinDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Investigational
ThalidomideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Vet Approved
ThiopentalDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved, Vet Approved
ThioridazineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved, Withdrawn
ThiothixeneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
TiagabineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved
TiaprideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Approved, Investigational
TiletamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.Vet Approved
TilidineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tilidine.Experimental
TizanidineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved
TolcaponeDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Withdrawn
ToloxatoneToloxatone may increase the anticholinergic activities of Doxylamine.Approved
TopiramateDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved
TramadolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the anticholinergic activities of Doxylamine.Experimental
TranylcypromineTranylcypromine may increase the anticholinergic activities of Doxylamine.Approved
TrazodoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Investigational
TriazolamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved
Tricaine methanesulfonateDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tricaine methanesulfonate.Vet Approved
TrichloroethyleneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Trichloroethylene.Approved
TrifluoperazineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
TrifluperidolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Trifluperidol.Experimental
TriflupromazineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Vet Approved
TrimipramineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved
TriprolidineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved
Valproic AcidDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Venlafaxine.Approved
VeraliprideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Veralipride.Experimental
VigabatrinDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.Approved
Vinyl etherDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Vinyl ether.Experimental
VortioxetineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
XenonDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Xenon.Experimental
XylazineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Xylazine.Vet Approved
ZaleplonDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved, Illicit, Investigational
ZiconotideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Zimelidine.Withdrawn
ZiprasidoneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved
ZolazepamDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Zolazepam.Vet Approved
ZolpidemDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Investigational
ZopicloneDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.Approved
ZotepineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Zotepine.Approved, Investigational
ZuclopenthixolDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB01936
KEGG Drug
D02327
PubChem Compound
3162
PubChem Substance
46506354
ChemSpider
3050
ChEBI
51380
ChEMBL
CHEMBL1004
Therapeutic Targets Database
DAP000859
PharmGKB
PA449419
Drugs.com
Drugs.com Drug Page
Wikipedia
Doxylamine
ATC Codes
R06AA59 — Doxylamine, combinationsR06AA09 — Doxylamine
AHFS Codes
  • 04:04.04 — Ethanolamine Derivatives
MSDS
Download (74 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAllergic Rhinitis (AR) / Upper Respiratory Infections1
3CompletedPreventionHyperemesis Gravidarum / Pregnancy1
3CompletedTreatmentNausea and Vomiting of Pregnancy1
4RecruitingTreatmentMorning Sickness1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Tablet, effervescentOral
Capsule; kitOral
CapsuleOral
KitOral
Tablet, delayed releaseOral
LiquidOral
Capsule, liquid filledOral
SyrupOral
Capsule, gelatin coatedOral
Tablet, coatedOral
TabletOral
SyrupOral9.75 mg/5mL
Tablet, film coatedOral
Kit; tabletOral
Powder, for solutionOral
SolutionOral
TabletOral25 mg
Kit
TabletOral25 mg/1
Prices
Unit descriptionCostUnit
Doxylamine succinate powder1.5USD g
Unisom sleep aid tablet0.34USD tablet
Sleep aid 25 mg tablet0.15USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6340695No2001-06-212021-06-21Us
US7560122No1999-01-252019-01-25Us
US9526703No2013-02-182033-02-18Us
US9375404No2013-02-182033-02-18Us
US9089489No2013-02-182033-02-18Us

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)< 25 °CPhysProp
boiling point (°C)139 °C at 5.00E-01 mm HgPhysProp
water solubility1 g/ml (succinate salt)Not Available
logP2.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.541 mg/mLALOGPS
logP2.9ALOGPS
logP2.96ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area25.36 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity82.24 m3·mol-1ChemAxon
Polarizability31.09 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9505
Blood Brain Barrier+0.9491
Caco-2 permeable+0.746
P-glycoprotein substrateSubstrate0.7449
P-glycoprotein inhibitor INon-inhibitor0.5123
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterInhibitor0.7507
CYP450 2C9 substrateNon-substrate0.8153
CYP450 2D6 substrateNon-substrate0.5432
CYP450 3A4 substrateSubstrate0.6801
CYP450 1A2 substrateNon-inhibitor0.9092
CYP450 2C9 inhibitorNon-inhibitor0.8957
CYP450 2D6 inhibitorInhibitor0.8361
CYP450 2C19 inhibitorNon-inhibitor0.8764
CYP450 3A4 inhibitorNon-inhibitor0.6894
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.736
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9183
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9218 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8765
hERG inhibition (predictor II)Inhibitor0.5398
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0ab9-9200000000-5a71de62862f9881c2a1
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-0040-0956300000-af11cf85a674e7db3735
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-001i-0910000000-b3cb895f045d519f2bf3
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-00kb-5597500000-8495062a84b32e776f33
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-1920000000-07b98b36c7ef5d9ad048
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-0900000000-1ae1143763892a7aac22
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-0900000000-460d58a5bb6a5eb5f55b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0159-0900000000-34dc5c06413efae437da
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0900000000-8a5f15b863b7129c1288
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0900000000-072ffba5139b7324d27a
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00lr-0900000000-fdf3fc57eff19bfe8fd8
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzylethers. These are aromatic ethers with the general formula ROCR' (R = alkyl, aryl; R'=benzene).
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzylethers
Direct Parent
Benzylethers
Alternative Parents
Pyridines and derivatives / Heteroaromatic compounds / Trialkylamines / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Benzylether / Pyridine / Heteroaromatic compound / Tertiary amine / Tertiary aliphatic amine / Azacycle / Organoheterocyclic compound / Ether / Dialkyl ether / Amine
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
tertiary amine, pyridines (CHEBI:51380)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes. Transactivates both the phenobarbital re...
Gene Name
NR1I3
Uniprot ID
Q14994
Uniprot Name
Nuclear receptor subfamily 1 group I member 3
Molecular Weight
39942.145 Da
References
  1. Dring AM, Anderson LE, Qamar S, Stoner MA: Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands. Chem Biol Interact. 2010 Dec 5;188(3):512-25. doi: 10.1016/j.cbi.2010.09.018. Epub 2010 Oct 20. [PubMed:20869355]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Not Available
Gene Name
CYP2B
Uniprot ID
Q14097
Uniprot Name
CYP2B protein
Molecular Weight
43147.81 Da
References
  1. Bookstaff RC, Murphy VA, Skare JA, Minnema D, Sanzgiri U, Parkinson A: Effects of doxylamine succinate on thyroid hormone balance and enzyme induction in mice. Toxicol Appl Pharmacol. 1996 Dec;141(2):584-94. [PubMed:8975784]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18